Trial · NCT07883369
Development and Evaluation of a Disease-oriented Scenario Game to Promote ACP Among Older Adults and Family Caregivers
NCT07883369, Not applicable, Not yet recruiting, Taipei Veterans General Hospital, Taiwan
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Development and Evaluation of a Disease-oriented Scenario Game to Promote ACP Among Older Adults and Family Caregivers. Trials, record NCT07883369. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07883369
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Development and Evaluation of a Disease-oriented Scenario Game to Promote ACP Among Older Adults and Family Caregivers
- NCT number
- NCT07883369
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 164 participants, estimated
- Lead sponsor
- Taipei Veterans General Hospital, Taiwan
- Conditions
- Heart Failure, Older Adults (65 Years and Older), Family Caregivers, Life Support Treatment, Tabletop Game
- Interventions
- tabletop game, ACP Exercise Book
- First posted
- 2026-10-20
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The Questionnaire on Life Support Preferences for Heart Failure Patients (QLSP-HF) | Baseline, Post-intervention immediately, Post-intervention one month | The questionnaire has 30 items and covers three scenarios and ten medical treatments. The scenarios include current health status, end-stage heart failure, and end-stage heart failure with loss of consciousness. The ten medical treatments assessed are antibiotics, inotropes, nasogastric tube feeding, intravenous fluids, cardiopulmonary resuscitation, ventilator support, dialysis, implantable cardioverter-defibrillators (ICDs), left ventricular assist device (LVAD), and heart transplantation. We use a 5-point Likert scale ranging from 1 (absolutely do not want) to 5 (absolutely want), yielding total scores from 30 to 150. Higher scores reflect a stronger preference for life-sustaining treatment. |
| Secondary | advance care planning (ACP) attitudes | Baseline, Post-intervention immediately, Post-intervention one month | The attitude section includes 12 questions about participants' feelings toward implementing ACP. A 5-point Likert scale is used, with scores ranging from "strongly disagree (1 point)" to "strongly agree (5 points)". The higher the total attitude score, the more positive the attitude towards ACP. |
| Secondary | advance care planning (ACP) behavioral intention | Baseline, Post-intervention immediately, Post-intervention one month | The behavioral intention section consists of 6 questions that concern the likelihood of implementing ACP in the future. These questions cover discussing future medical decisions with family, friends, or healthcare professionals; participating in ACP consultations; and signing advance directives (ADs). The scoring system ranges from "very unlikely (1 point)" to "very likely (5 points)". The higher the total score for behavioral intention, the more positive the behavioral intention for ACP. |
| Secondary | State-Trait Anxiety Inventory- State Anxiety Scale (STAI-S) | Baseline, Post-intervention immediately, Post-intervention one month | STAI-S is used to measure an individual's current anxiety level. It uses a 4-point Likert scale, ranging from "almost none (1 point)" to "almost all (4 points)", with a score range of 20 to 80 points; the higher the score, the higher the level of anxiety. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07883369
GET https://conductscience.org/api/trials/v1/NCT07883369/registered